Groneberg D A, Witt C, Wagner U, Chung K F, Fischer A
Department of Pediatric Pneumology and Immunology, Charité School of Medicine, Humboldt University, Berlin, Germany.
Respir Med. 2003 Apr;97(4):382-7. doi: 10.1053/rmed.2002.1457.
Aerosol administration of peptide-based drugs plays an important role in the treatment of pulmonary and systemic diseases and the unique cellular properties of airway epithelium offers a great potential to deliver new compounds. As the relative contributions from the large airways to the alveolar space are important to the local and systemic availability, the sites and mechanism of uptake and transport of different target compounds have to be characterized. Among the different respiratory cells, the ciliated epithelial cells of the larger and smaller airways and the type I and type II pneumocytes are the key players in pulmonary drug transport. With their diverse cellular characteristics, each of these cell types displays a unique uptake possibility. Next to the knowledge of these cellular aspects, the nature of aerosolized drugs, characteristics of delivery systems and the depositional and pulmonary clearance mechanisms display major targets to optimize pulmonary drug delivery. Based on the growing knowledge on pulmonary cell biology and pathophysiology due to modern methods of molecular biology, the future characterization of pulmonary drug transport pathways can lead to new strategies in aerosol drug therapy.
基于肽的药物的雾化给药在肺部和全身性疾病的治疗中发挥着重要作用,气道上皮独特的细胞特性为递送新化合物提供了巨大潜力。由于大气道对肺泡空间的相对贡献对局部和全身可用性很重要,因此必须表征不同靶化合物的摄取和转运部位及机制。在不同的呼吸细胞中,大小气道的纤毛上皮细胞以及I型和II型肺细胞是肺部药物转运的关键参与者。由于它们具有多样的细胞特性,每种细胞类型都表现出独特的摄取可能性。除了了解这些细胞方面的知识外,雾化药物的性质、递送系统的特性以及沉积和肺部清除机制也是优化肺部药物递送的主要目标。基于现代分子生物学方法对肺细胞生物学和病理生理学的认识不断增加,未来对肺部药物转运途径的表征可能会带来雾化药物治疗的新策略。